0001193125-19-316526.txt : 20191218 0001193125-19-316526.hdr.sgml : 20191218 20191217210911 ACCESSION NUMBER: 0001193125-19-316526 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20191217 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191218 DATE AS OF CHANGE: 20191217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 191291147 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 8-K 1 d835112d8k.htm 8-K 8-K
NYSE A1 false 0000885590 0000885590 2019-12-17 2019-12-17

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): December 17, 2019

(December 17, 2019)

 

Bausch Health Companies Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

British Columbia, Canada

 

001-14956

  

98-0448205

(State or Other Jurisdiction

of Incorporation or Organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

2150 St. Elzéar Blvd. West

Laval, Quebec

Canada H7L 4A8

(Address of Principal Executive Offices)(Zip Code)

514-744-6792

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Shares, No Par Value

  

BHC

  

New York Stock Exchange, Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

Item 8.01 Other Events.

Unsecured Notes Offering

On December 17, 2019, Bausch Health Companies Inc. (the “Company”) announced that it priced a previously announced offering of $1,250,000,000 aggregate principal amount of 5.000% senior notes due 2028 (the “2028 Notes”) and $1,250,000,000 aggregate principal amount of 5.250% senior notes due 2030 (the “2030 Notes” and, together with the 2028 Notes, the “Notes”). The aggregate size of the offering of the Notes is $2,500,000,000, which reflects an increase of $1,250,000,000 from the previously announced offering size of $1,250,000,000. The offering price for the 2028 Notes was 100.00% of the principal amount thereof and the offering price for the 2030 Notes was 100.00% of the principal amount thereof. The Notes will be offered in the United States to qualified institutional investors pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.

The Company also issued press releases pursuant to Rule 135c under the Securities Act relating to the offering of the Notes. In accordance with Rule 135c(d) under the Securities Act, copies of the press releases are attached hereto as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, which are incorporated herein by reference.

The foregoing is qualified by reference to the press releases that are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, which are incorporated herein by reference.

This Current Report on Form 8-K and the press releases attached hereto as Exhibits 99.1 and 99.2 do not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. These securities will not be registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit
Number

    

Description

         
 

99.1

    

Press release announcing the launch of the notes offering, dated December 17, 2019

         
 

99.2

    

Press release announcing the pricing of the notes offering, dated December 17, 2019

         
 

104

    

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

EXHIBIT INDEX

Exhibit

Number

    

Description

         
 

99.1

    

Press release announcing the launch of the notes offering, dated December 17, 2019

         
 

99.2

    

Press release announcing the pricing of the notes offering, dated December 17, 2019

         
 

104

    

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BAUSCH HEALTH COMPANIES INC.

     

By:

  

/s/ Paul S. Herendeen

Name:

  

Paul S. Herendeen

Title:

  

Executive Vice President, Chief Financial Officer

Date: December 17, 2019

 EX-99.1 2 d835112dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

Investor Contact:    Media Contact:
Arthur Shannon    Lainie Keller
arthur.shannon@bauschhealth.com    lainie.keller@bauschhealth.com
(514) 856-3855    (908) 927-1198
(877) 281-6642 (toll free)   

BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR NOTES

LAVAL, Quebec, Dec. 17, 2019 — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that it has launched an offering of a combined $1,250,000,000 aggregate principal amount of new senior notes due 2028 (the “2028 Notes”) and new senior notes due 2030 (the “2030 Notes” and, together with the 2028 Notes, the “Notes”). Bausch Health intends to use the proceeds from the offering of the Notes to finance amounts owed under the Company’s recently announced $1.21 billion settlement agreement (the “Settlement”) relating to the U.S. putative securities class litigation filed in the U.S. District Court for the District of New Jersey (which is subject to court approval) and to pay transaction fees and expenses, with any remaining proceeds going to cash on the balance sheet for general corporate purposes.

The Notes will be guaranteed by each of the Company’s subsidiaries that are guarantors under the Company’s credit agreement and existing senior notes. Consummation of the offering of the Notes is subject to market and other conditions, and there can be no assurance that the Company will be able to successfully complete this transaction on the terms described above, or at all.

The Notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Forward-looking Statements

This news release may contain forward-looking statements, including, but not limited to, our financing plans, including the offering of the Notes and the details thereof, including the proposed use of proceeds therefrom, the pending Settlement and other expected effects of the offering of the Notes. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the U.S. District Court for the District of New Jersey may not approve the Settlement, other risks related to our business, including risks related to our pending legal and governmental proceedings, legislative and policy efforts, actions by the U.S. Food and Drug Administration and other regulators, our substantial debt, uncertainties associated with acquisitions and product launches, particularly in light of our active consideration of acquisition opportunities within our core therapeutic areas, some of which could be sizable, and risks and uncertainties discussed in our most recent annual and quarterly reports and detailed from time to time in our other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. We undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, except as required by law.

###

 

Page  |  2

EX-99.2 3 d835112dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

Investor Contact:       Media Contact:
Arthur Shannon       Lainie Keller
arthur.shannon@bauschhealth.com       lainie.keller@bauschhealth.com
(514) 856-3855       (908) 927-1198
(877) 281-6642 (toll free)      

BAUSCH HEALTH ANNOUNCES PRICING OF PRIVATE OFFERING OF SENIOR NOTES

LAVAL, Quebec, Dec. 17, 2019 — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that it has priced its previously announced offering of $1,250,000,000 aggregate principal amount of 5.000% senior notes due 2028 (the “2028 Notes”) and $1,250,000,000 aggregate principal amount of 5.250% senior notes due 2030 (the “2030 Notes” and, together with the 2028 Notes, the “Notes”). The aggregate size of the offering of the Notes is $2,500,000,000, which reflects an increase of $1,250,000,000 from the previously announced offering size of $1,250,000,000. The 2028 Notes will be sold to investors at a price of 100% of the principal amount thereof and the 2030 Notes will be sold to investors at a price of 100% of the principal amount thereof. Bausch Health intends to use the proceeds from the offering of the Notes, along with cash on hand, to finance amounts owed under the Company’s recently announced $1.21 billion settlement agreement (the “Settlement”) relating to the U.S. putative securities class litigation filed in the U.S. District Court for the District of New Jersey (which is subject to court approval), and redeem $1.24 billion aggregate principal amount of the Company’s outstanding 5.875% Senior Notes due 2023, as well as to pay related fees and expenses.

The Notes will be guaranteed by each of the Company’s subsidiaries that are guarantors under the Company’s credit agreement and existing senior notes. Consummation of the offering of the Notes is subject to various closing conditions, and there can be no assurance that the Company will be able to successfully complete this transaction on the terms described above, or at all.

The Notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Forward-looking Statements

This news release may contain forward-looking statements, including, but not limited to, our financing plans, including the offering of the Notes and the details thereof, including the proposed use of proceeds therefrom, the pending Settlement and other expected effects of the offering of the Notes. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the U.S. District Court for the District of New Jersey may not approve the Settlement, other risks related to our business, including risks related to our pending legal and governmental proceedings, legislative and policy efforts, actions by the U.S. Food and Drug Administration and other regulators, our substantial debt, uncertainties associated with acquisitions and product launches, particularly in light of our active consideration of acquisition opportunities within our core therapeutic areas, some of which could be sizable, and risks and uncertainties discussed in our most recent annual and quarterly reports and detailed from time to time in our other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. We undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, except as required by law.

###

Page | 2

EX-101.SCH 4 bhc-20191217.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 bhc-20191217_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 bhc-20191217_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g835112g42w00.jpg GRAPHIC begin 644 g835112g42w00.jpg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v3.19.3.a.u2
Document and Entity Information
Dec. 17, 2019
Cover [Abstract]  
Security Exchange Name NYSE
Entity Incorporation, State or Country Code A1
Amendment Flag false
Entity Central Index Key 0000885590
Document Type 8-K
Document Period End Date Dec. 17, 2019
Entity Registrant Name Bausch Health Companies Inc.
Entity File Number 001-14956
Entity Tax Identification Number 98-0448205
Entity Address, Address Line One 2150 St. Elzéar Blvd. West
Entity Address, City or Town Laval
Entity Address, State or Province QC
Entity Address, Country CA
Entity Address, Postal Zip Code H7L 4A8
City Area Code 514
Local Phone Number 744-6792
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, No Par Value
Trading Symbol BHC
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "6ID4\?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ ):F13R?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " EJ9%/A0_-J.X K @ $0 &1O8U!R;W!S+V-O M&ULS9+!2L0P$(9?17)O)^FBLJ';B^))07!!\1:2V=U@DX9DI-VW-XV[ M740?P&-F_GSS#4RK@]1#Q.X2&\QMP2,HH4C #J[ 06=<:+75$14,\X8U>\.$S]@5F-&"/ M#CTE$+4 ULT3PW'J6[@ 9AAA=.F[@&8AENJ?V-(!=DI.R2ZI<1SK<55R>0?)KZN[^^T#ZQHNUI5H*G&[;83D:\FOWV?7 M'WX783<8N[/_V/@LV+7PZRZZ+U!+ P04 " EJ9%/F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( "6ID4\*".CEJ0( /D+ 8 >&PO=V]R:W-H965T&UL=5;MCILP$'P5Q ,=^;+ M5;.3'%7T3SI[[H:A]OX^C"K^S>Z%HQ!;R?:,12,#I'2JQ@WS?:@02\)JD M>)Q26,&W&\,$#">!T!)8P?<-0)3#(%[B.8D/MXW@F,,P7N0TP6&POR@59MTSZ8Y""68CNS'0K[];M 6TTQ&?F2V+Y[?/?<!,18V(I/FO)%: MF[_W/!.G*)AIJQPEG2R5%LS24J\\DVMDB4D1K\"QZJ0 M]KP118WAP/#AP X_JK@0*"TPF' Z\T?3+'N U!MPFA M'_2KAV.U1@T_1PMC-8OMK^KY#.-"EQ=,-G'*Y KAC@FL6MU]GTVJ>R^!Q4KG M2N]":\+,,HN@-.S2TEMZ)P[<*'!V*-]DE_-EQE;5TR7+C /R=/^8G#3+*(X$ M-W"#VZJ=3T^OU^GT?8>X9Y[GV]R![[5N:NVGJ+DJ2Y/ 1TJWKB"O3DX.E>0I M\*^XXF51".\0Y1>L($W!%;+,IL2BR)GD:$J^VS6(ESRC\A5B@=HE(6@%4;]S M5N,Z9QNX3B@WON3QKI0U0/U>RX^B7NAW:I!&2:+1F.;S!]QRB7 OG03#H..3 M7-HPR?Z\>1V>GGY@&BZR==*&!S3V&/RX7)'.YNK1Z8A;MF;9,8 7I4ZU6G,9 M.P%^&1^-8:]QI^=&QQRGREC2[ ^>'^R/J^XM1*.>@[O#H&%RT*D31 X/*J9; MIJF2=;KH1E'KK-L/J_L/-!,LRE)W@L;47A+&&1XJXS&W7*[@,Y&IN]1HU.$^E^N72C<8ROC2G(^'\^YYD[!X4@4<]2 M1A5HPIV"*&POC"@J"RL.?!U[2=MH'<3*?'=G^]2=/;T0?Q MX(.^-#/?3+[YGTP!07FA:9'M23PIY49M"8TQ-E1=88O2-W- (^E2L@%RYS M^LBE*)V8<[D2BF0TR0@_6L,)]$+*A<>);1Q 62Q0OR62_I/ M@=7KO2NDW 2F- )%9CDB./WDG3EY!G\)D<4^3]8K;!V?DO2>[A/FP1S'A13MK_Z_O,M_HI@MW7-HT:L&W5!2#D*B MT(O&3M0U1'GAA_GUM#P0>)S6/$HQ:#>S@7WOT3Q U!+ P04 " EJ9%/%FTC?T,! \ M @ #P 'AL+W=O+N)!NRPH_(WD#+UW?M*(7>>K)W=CP[.UZT)-X%>*X-F[OD.[+^1$B@9]H&V:9U>Q49ZQ!/"+[(#3UC](9(J/Q1[+>0L9\$C!BQ1 M(WT7,MTU2-XBNUHCY3">0XAS_Y\87=-@!2M7]08L#3EZT'&Z#2UV00JK#!1R MI AE:_%HB=V(M1VDF!MWX='K>MB+.+&+6>'GR V_KB?)^.BVA@8MU&\\(##. M(50;+^*1=*:W=Y-[#KO7^H&Q=_OJ5-*/&N/'+7\ 4$L#!!0 ( "6ID4__ MP"8(O0 (4" : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.MDD$* M@S 0 +\B>4!7;>FAJ*=>O+;]0-#5B)J$[);J[YMZ44&A!R\)8LX'LQYT4,CQT>7S%1]_276<]>@C"MA[_)1/TU MP.K795]02P,$% @ ):F13PN/V ,A 0 5P0 !, !;0V]N=&5N=%]4 M>7!E&ULM51-3\,P#/TK4Z]HS># 6V[ %>8!'\@)&X;-5^RO=']>]QN M0V(J8FC;)8GS[/=>$BOS]VT&FG3!1UH4#7-^4(I, T%3F3)$0:J$0;.$6*NL M3:MK4'>SV;TR*3)$GG+/42SG3U#IM>?)XVZ_IUX4.F?OC&:7HMI$>T0ZW1.6 M"'[(H<9ENI&$8O+<"0O)WJ(0E IU@L)Q81]+W>L&$)V%?UE+5>4,V&3604I* MR@C:4@/ P9?4: 3[QNABO?>[TL@O.@BQZKSZD5!>SP=O/8P;&)!+*K.T!8Q) M#PGPG;83UV MX=\@J6$Z[];_:'29RZ!=_,W(1TKM05\-_\GR"U!+ 0(4 Q0 ( "6ID4\? M(\\#P !," + " 0 !?D !D;V-0 M&UL4$L! A0#% @ ):F13X4/S:CN *P( !$ M ( !F0$ &1O8U!R;W!S+V-O&UL4$L! A0#% @ ):F1 M3YE&PO=V]R:W-H965T&UL4$L! A0#% @ ):F1 M3TLBJ_)E @ / 8 !0 ( !U@L 'AL+W-H87)E9%-T&UL4$L! A0#% @ ):F13[JA.8K7 0 ,@8 T M ( !;0X 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% M @ ):F13__ )@B] A0( !H ( !WQ$ 'AL+U]R96QS M+W=O ZIP 10 0001193125-19-316526-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-316526-xbrl.zip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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d835112d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d835112d8k.htm" ] }, "labelLink": { "local": [ "bhc-20191217_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bhc-20191217_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bhc-20191217.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bhc", "nsuri": "http://www.bauschhealth.com/20191217", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d835112d8k.htm", "contextRef": "duration_2019-12-17_to_2019-12-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d835112d8k.htm", "contextRef": "duration_2019-12-17_to_2019-12-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.bauschhealth.com//20191217/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d835112d8k.htm bhc-20191217.xsd bhc-20191217_lab.xml bhc-20191217_pre.xml d835112dex991.htm d835112dex992.htm http://xbrl.sec.gov/dei/2019-01-31 true false XML 17 d835112d8k_htm.xml IDEA: XBRL DOCUMENT 0000885590 2019-12-17 2019-12-17 NYSE A1 false 0000885590 8-K 2019-12-17 Bausch Health Companies Inc. 001-14956 98-0448205 2150 St. Elzéar Blvd. West Laval QC CA H7L 4A8 514 744-6792 false false false false Common Shares, No Par Value BHC false